Session Title: Microbiome: Ready for Prime Time in immuno-oncology?
In less than a decade, several discoveries propelled the gut microbiome from the dark matter to one of the “hallmarks of cancer”. Recent studies revealed that the baseline microbiome composition correlated with the anti-cancer response, the risk of immune-related toxicities and the development of graft-versus-host disease (GVHD). This intricate relationship is linked through several mechanisms including microbiome-associated molecular patterns, cross-reactive antigens, bacterial metabolites and immune checkpoint expression.
Furthermore, harnessing the microbiome using fecal microbiota transplantation, probiotics and prebiotics demonstrated that shifting the microbiome composition can enhance immune checkpoint inhibitors (ICI) response and improve GVHD. In this session, we will focus on the development of user-friendly strategies to profile microbiome composition as a novel biomarker. We will review the ongoing strategies to improve the microbiome composition for patients amenable to ICI treatment or allogeneic stem cell transplantation. In sum, the aim of this session is to understand and review the mechanisms by which bugs can become new cancer drugs.